Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC

NCT ID: NCT06597513

Last Updated: 2024-10-15

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-31
• Study Completion Date: 2026-12-31

Brief Summary

The goal of this clinical trial is to learn if hematopoietic stem cell transplantation-supported dose-dense chemotherepy with adebrelimb works to treat extensive-stage small-cell lung cancer in adults. It will also assess the safety of this treatment approach.

The main questions it aims to answer are:

Does hematopoietic stem cell transplantation-supported dose-dense chemotherepy with adebrelimb improve the median progression free survival and 12-months overall survival rates? What medical problems do participants experience whild undergoing this treatment?

Participants will:

Complete two 21-days cycles of standard-dose etoposide and carboplatin, followed by G-CSF for stem cell mobilization.

Receive dose-dense chemotherapy followed by autologous stem cell reinfusion for two 21-day cycles.

If eligible, participants will receive etoposide and carboplatin plus adebrelimab for four cycles.

Finally, participants may enter a maintenance phase with adebrelimab.

Throughout the trial, participants will:

Visit the clinic every 21 days for check-ups and tests. Imaging examination every 6 weeks. Followed up by telephone every 2 months

Conditions

Extensive Stage Small Cell Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab

Complete two 21-days cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1, followed by G-CSF for stem cell mobilization. Receive dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 followed by autologous stem cell reinfusion for two 21-day cycles. If eligible, participants will receive standaed-dose etoposide and carboplatin plus adebrelimab 1200 mg on day 1 for four cycles. Finally, participants may enter a maintenance phase with adebrelimab1200 mg every 21 days.

Group Type: EXPERIMENTAL

auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab

Intervention Type: DRUG

Induction:

Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.

Those without disease progression will advance to consolidation treatment.

Consolidation:

Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.

After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.

Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.

Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.

Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.

Maintenance:

Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision.

Interventions

auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab

Induction:

Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.

Those without disease progression will advance to consolidation treatment.

Consolidation:

Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.

After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.

Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.

Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.

Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.

Maintenance:

Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision.

Intervention Type: DRUG

Other Intervention Names

auto-HSCT, Dose-Dense Chemotherapy, Adebrelimab

Eligibility Criteria

Inclusion Criteria

1. Pathologically confirmed small cell lung cancer (SCLC) staged as extensive-stage (ES-SCLC) according to the Veterans Administration Lung Study Group (VALG) classification.

2. ES-SCLC dose not received prior systemic treatment.

3. History of localized-stage SCLC with prior radiotherapy and chemotherapy, with the requirement for definitive treatment, and a minimum of 6 months interval from the last treatment to diagnosis of ES-SCLC.

4. CT or MRI scan ≤28 days prior to the first dose of study medication, with at least one target lesion that has not been irradiated (RECIST v1.1 criteria).

5. Male or female patients aged ≥18 and ≤70 years.

6. ECOG Performance Status of 0 or 1.

7. Life expectancy ≥12 weeks.

8. Adequate organ system function (excluding use of any blood components or growth factors during screening).

9. Male or female participants must agree to use appropriate contraception (e.g., intrauterine device, contraceptive pills, or condoms) from the start of the study treatment until 6 months after the last study treatment; women of childbearing potential must have a negative pregnancy test within 7 days prior to enrollment.

10. Subjects voluntarily participate in this study and sign the informed consent form (ICF).

Exclusion Criteria

1. Histologically or cytologically confirmed mixed SCLC and NSCLC.

2. Prior treatment with any T-cell co-stimulatory or immune checkpoint inhibitors, including but not limited to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors, or other T-cell targeted agents.

3. Prior treatment with vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) inhibitors.

4. Symptomatic brain metastases, leptomeningeal disease, or spinal cord compression. For treated brain metastases, the following criteria must be met: no progression on MRI ≥4 weeks post-treatment, completion of treatment ≥28 days before the first dose of study drug, and no need for systemic corticosteroids (>10 mg/day prednisone or equivalent) ≤14 days before the first dose.

5. Hematologic disorders including, but not limited to, lymphoma, acute or chronic leukemia, multiple myeloma, aplastic anemia, or myelodysplastic syndromes.

6. Symptomatic third-space fluid accumulation, such as uncontrolled pericardial effusion, pleural effusion, or ascites despite drainage or other treatments.

7. Active, known, or suspected autoimmune diseases. Exceptions include vitiligo, type 1 diabetes, autoimmune thyroiditis with only hormone replacement therapy, or conditions unlikely to relapse without external stimuli.

8. Use of systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressants ≤14 days before the first dose of study drug. Inhaled or topical corticosteroids and adrenal replacement therapy are allowed if no active autoimmune disease.

9. Receipt of or planned vaccination with live vaccines ≤4 weeks before the first dose of study drug.

10. Interstitial lung disease, drug-induced pneumonitis, radiation pneumonitis requiring corticosteroids, active pneumonia, or severe pulmonary dysfunction.

11. Active tuberculosis or history of active tuberculosis ≤48 weeks before screening, regardless of treatment status.

12. Toxicities from prior anticancer treatment other than alopecia and fatigue must have resolved to CTCAE v4.03 ≤ Grade 1 before the first dose. Long-term sequelae such as platinum-based neurotoxicity are allowed if anticipated to be stable.

13. Imaging (CT or MRI) showing tumor invasion of major vessels, hemoptysis symptoms within 3 months before screening, or daily hemoptysis ≥2.5 mL.

14. Minor surgery (including catheter placement) ≤48 hours before the first dose of study drug.

15. Current or recent use of aspirin (>325 mg/day) or other nonsteroidal anti-inflammatory drugs known to inhibit platelet function ≤10 days before the first dose.

16. Current or recent use of full-dose oral or parenteral anticoagulants or thrombolytics ≤10 days before the first dose. Preventive anticoagulation is allowed.

17. Known hereditary bleeding disorders or coagulation dysfunction. Significant bleeding symptoms or clear bleeding tendencies (e.g., gastrointestinal bleeding, bleeding ulcers, baseline stool occult blood ++ or more) within 12 weeks before screening.

18. History of thromboembolic events within 24 weeks before signing the ICF, including stroke (including transient ischemic attack, hemorrhagic stroke, or infarction), deep vein thrombosis, or pulmonary embolism.

19. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), hypertensive crises, or history of hypertensive encephalopathy.

20. History of gastrointestinal ulcers, perforation, corrosive esophagitis or gastritis, inflammatory bowel disease, diverticulitis, abdominal fistula, tracheoesophageal fistula, or intra-abdominal abscess within 24 weeks before signing the ICF.

21. Uncontrolled cardiac symptoms or diseases, including: (1) NYHA Class ≥II heart failure; (2) unstable angina; (3) myocardial infarction within 24 weeks; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.

22. Known allergy to study drug or excipients, or a history of severe allergic reactions to any monoclonal antibody.

23. Other malignancies within 5 years before the first dose, except for adequately treated cervical carcinoma in situ, basal cell carcinoma, squamous cell carcinoma of the skin, locally excised prostate cancer, or ductal carcinoma in situ with minimal risk of metastasis and expected cure.

24. Known psychiatric disorders, alcohol abuse, drug abuse, or substance misuse.

25. Positive HBsAg with HBV DNA levels exceeding normal limits (1000 copies/ml or 500 IU/ml), or positive HCV (HCV RNA or HCV Ab indicating acute or chronic infection); known HIV positive or acquired immunodeficiency syndrome (AIDS).

26. Uncontrolled or symptomatic hypercalcemia.

27. Receipt of any investigational drug or participation in another interventional clinical trial ≤4 weeks before signing the ICF.

28. History of allogeneic bone marrow transplantation or solid organ transplantation.

29. Use of systemic immunosuppressive drugs ≤2 weeks before randomization.

30. History of hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins, carboplatin, or etoposide.

31. Any other factors that, in the investigator's judgment, may lead to premature discontinuation of the study, including non-compliance, severe concurrent illness (including psychiatric illness), significant laboratory abnormalities, or factors affecting the safety or data collection.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhou Chengzhi

OTHER

Sponsor Role: lead

Responsible Party

Zhou Chengzhi

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Chengzhi Zhou, MD

Role: STUDY_DIRECTOR

The First Affiliated Hospital of Guang Zhou Medical University

Central Contacts

Chengzhi Zhou, MD

Role: CONTACT

doctorzcz@163.com

13560351186

Ming Liu, MD

Role: CONTACT

mingliu128@hotmail.com

18688380929

References

Liu M, Guan W, Xie X, Li Z, Qiu G, Lin X, Xie Z, Zhang J, Qin Y, Huang Z, Xu X, Zhou C. Phase I Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation-Supported Dose-Intensified Chemotherapy With Adebrelimab as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer. Clin Lung Cancer. 2025 May;26(3):e236-e241. doi: 10.1016/j.cllc.2024.12.013. Epub 2024 Dec 27.

Reference Type: DERIVED

PMID: 39848827 (View on PubMed)

Other Identifiers

CROC-24-07

Identifier Type: -

Identifier Source: org_study_id